Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells
Figure 6
Effect of doxorubicin and decursin on mTOR pathway in multiple myeloma cells. (a) Effect of pervanadate on the STAT3 inactivation, SHP-2 activation, and cleavages of caspase-3 and PARP induced by combination of decursin and doxorubicin in U266 cells. (b) Effect of combination of decursin and doxorubicin on the phosphorylation of mTOR, S6 K1, and ERK in U266, MM1.S, and RPMI8226 cells. The cells were treated with decursin and/or doxorubicin for 24 h. Western blotting was performed with antibodies of mTOR, phospho-mTOR, phospho-S6 K1, phospho-ERK, and -actin.
